FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

In the abrysvo or arexvy market, companies aim to expand the vaccine's use across a wider range of age groups by focusing on broader age indications. An example is Pfizer Inc., which received FDA ...

Moderna has secured FDA approval for its respiratory syncytial ... score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding differences in study design ...

Abrysvo was only a few weeks behind with an FDA approval for the same age group on 31st May, Since then, Abrysvo has also been approved as a maternal vaccine to prevent RSV in newborns ...

The FDA recently submitted a proposed front-of-package labeling rule to the Office of Information and Regulatory Affairs. This proposed rule takes us one step closer to advancing a strong front-of ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.